Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.56 Million GBP | -51.94% |
| 2022 | 3.25 Million GBP | -57.4% |
| 2021 | 7.63 Million GBP | 124.19% |
| 2020 | 3.4 Million GBP | 87.4% |
| 2019 | 1.81 Million GBP | 133.98% |
| 2018 | 777 Thousand GBP | -29.56% |
| 2017 | 1.1 Million GBP | 28.26% |
| 2016 | 860 Thousand GBP | -8.12% |
| 2015 | 936 Thousand GBP | 89.09% |
| 2014 | 495 Thousand GBP | 8.32% |
| 2013 | 457 Thousand GBP | 16.88% |
| 2012 | 391 Thousand GBP | -57.59% |
| 2011 | 922 Thousand GBP | 74.95% |
| 2010 | 527 Thousand GBP | -20.99% |
| 2009 | 667 Thousand GBP | 14.02% |
| 2008 | 585 Thousand GBP | 23.94% |
| 2007 | 472 Thousand GBP | 37.21% |
| 2006 | 344 Thousand GBP | -13.57% |
| 2005 | 398 Thousand GBP | 144.17% |
| 2004 | 163 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 1.56 Million GBP | 0.0% |
| 2023 Q1 | 2.74 Million GBP | -15.73% |
| 2023 FY | 1.56 Million GBP | -51.94% |
| 2023 Q3 | 1.56 Million GBP | -42.96% |
| 2023 Q2 | 2.74 Million GBP | 0.0% |
| 2022 Q3 | 3.25 Million GBP | -29.66% |
| 2022 Q2 | 4.62 Million GBP | 0.0% |
| 2022 FY | 3.25 Million GBP | -57.4% |
| 2022 Q1 | 4.62 Million GBP | -39.43% |
| 2022 Q4 | 3.25 Million GBP | 0.0% |
| 2021 Q3 | 7.63 Million GBP | 52.94% |
| 2021 Q2 | 4.99 Million GBP | 0.0% |
| 2021 FY | 7.63 Million GBP | 124.19% |
| 2021 Q1 | 4.99 Million GBP | 46.58% |
| 2021 Q4 | 7.63 Million GBP | 0.0% |
| 2020 FY | 3.4 Million GBP | 87.4% |
| 2020 Q1 | 2.18 Million GBP | 20.24% |
| 2020 Q2 | 2.18 Million GBP | 0.0% |
| 2020 Q4 | 3.4 Million GBP | 0.0% |
| 2020 Q3 | 3.4 Million GBP | 55.86% |
| 2019 Q1 | 988 Thousand GBP | 27.16% |
| 2019 Q3 | 1.81 Million GBP | 84.01% |
| 2019 Q4 | 1.81 Million GBP | 0.0% |
| 2019 FY | 1.81 Million GBP | 133.98% |
| 2019 Q2 | 988 Thousand GBP | 0.0% |
| 2018 Q1 | 926 Thousand GBP | -16.05% |
| 2018 FY | 777 Thousand GBP | -29.56% |
| 2018 Q4 | 777 Thousand GBP | 0.0% |
| 2018 Q3 | 777 Thousand GBP | -16.09% |
| 2018 Q2 | 926 Thousand GBP | 0.0% |
| 2017 Q1 | 653 Thousand GBP | -24.07% |
| 2017 Q4 | 1.1 Million GBP | 0.0% |
| 2017 FY | 1.1 Million GBP | 28.26% |
| 2017 Q3 | 1.1 Million GBP | 68.91% |
| 2017 Q2 | 653 Thousand GBP | 0.0% |
| 2016 Q1 | 721 Thousand GBP | -22.97% |
| 2016 FY | 860 Thousand GBP | -8.12% |
| 2016 Q4 | 860 Thousand GBP | 0.0% |
| 2016 Q3 | 860 Thousand GBP | 19.28% |
| 2016 Q2 | 721 Thousand GBP | 0.0% |
| 2015 Q4 | 936 Thousand GBP | 0.0% |
| 2015 Q2 | 503 Thousand GBP | 0.0% |
| 2015 Q1 | 503 Thousand GBP | 1.62% |
| 2015 Q3 | 936 Thousand GBP | 86.08% |
| 2015 FY | 936 Thousand GBP | 89.09% |
| 2014 Q3 | 495 Thousand GBP | -65.65% |
| 2014 Q4 | 495 Thousand GBP | 0.0% |
| 2014 Q2 | 1.44 Million GBP | 0.0% |
| 2014 Q1 | 1.44 Million GBP | 215.32% |
| 2014 FY | 495 Thousand GBP | 8.32% |
| 2013 Q4 | 457 Thousand GBP | 0.0% |
| 2013 Q2 | 454 Thousand GBP | 0.0% |
| 2013 FY | 457 Thousand GBP | 16.88% |
| 2013 Q1 | 454 Thousand GBP | 16.11% |
| 2013 Q3 | 457 Thousand GBP | 0.66% |
| 2012 Q4 | 391 Thousand GBP | 0.0% |
| 2012 Q2 | 692 Thousand GBP | 0.0% |
| 2012 FY | 391 Thousand GBP | -57.59% |
| 2011 FY | 922 Thousand GBP | 74.95% |
| 2011 Q2 | 922 Thousand GBP | 0.0% |
| 2010 Q2 | 527 Thousand GBP | 0.0% |
| 2010 Q4 | 608 Thousand GBP | 0.0% |
| 2010 FY | 527 Thousand GBP | -20.99% |
| 2009 Q2 | 667 Thousand GBP | 0.0% |
| 2009 Q4 | 720 Thousand GBP | 0.0% |
| 2009 FY | 667 Thousand GBP | 14.02% |
| 2008 Q4 | 544 Thousand GBP | 0.0% |
| 2008 Q2 | 585 Thousand GBP | 0.0% |
| 2008 FY | 585 Thousand GBP | 23.94% |
| 2007 Q2 | 472 Thousand GBP | 0.0% |
| 2007 Q4 | 563 Thousand GBP | 0.0% |
| 2007 FY | 472 Thousand GBP | 37.21% |
| 2006 Q4 | 380 Thousand GBP | 0.0% |
| 2006 FY | 344 Thousand GBP | -13.57% |
| 2006 Q2 | 344 Thousand GBP | 0.0% |
| 2005 Q4 | 421 Thousand GBP | 0.0% |
| 2005 FY | 398 Thousand GBP | 144.17% |
| 2005 Q2 | 398 Thousand GBP | 0.0% |
| 2004 Q2 | 163 Thousand GBP | 0.0% |
| 2004 Q4 | - GBP | 0.0% |
| 2004 FY | 163 Thousand GBP | 0.0% |
| 2003 Q4 | 34 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.066% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 83.678% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.874% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.842% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.35% |
| Mesoblast Limited | 188.44 Million USD | 99.17% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 59.392% |
| Genus plc | 485 Million USD | 99.678% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 73.231% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 37.846% |
| Marizyme, Inc. | 26.67 Million USD | 94.137% |
| ContraFect Corporation | 32.53 Million USD | 95.192% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 58.842% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 21.062% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 59.139% |
| Intellipharmaceutics International Inc. | 12 Million USD | 86.976% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 86.721% |
| MultiCell Technologies, Inc. | 1617.67 USD | -96582.265% |
| Accustem Sciences Inc. | 1.07 Million USD | -44.917% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.98% |
| EV Biologics, Inc. | 2.11 Million USD | 26.054% |
| Q BioMed Inc. | 8.13 Million USD | 80.77% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.114% |
| Neon Bloom, Inc. | 1.22 Million USD | -27.547% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 69.608% |
| Biomind Labs Inc. | 1.49 Million USD | -4.363% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.359% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.502% |
| Skye Bioscience, Inc. | 14.07 Million USD | 88.886% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 22.194% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1000.672% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 83.478% |
| IMV Inc. | 37.93 Million USD | 95.877% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -677.661% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 72.78% |
| GB Sciences, Inc. | 5.41 Million USD | 71.131% |
| Alpha Cognition Inc. | 7.16 Million USD | 78.171% |
| HST Global, Inc. | 593.59 Thousand USD | -163.48% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Halberd Corporation | 728.71 Thousand USD | -114.623% |
| Enzolytics Inc. | 365.26 Million USD | 99.572% |
| Resverlogix Corp. | 67.39 Million USD | 97.679% |
| Affymax, Inc. | 8.87 Million USD | 82.37% |
| SYBLEU INC | 681.41 Thousand USD | -129.523% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -86.472% |
| argenx SE | 444.95 Million USD | 99.649% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.912% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 8.751% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 86.861% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 57.328% |
| AVAX Technologies, Inc. | 3.99 Million USD | 60.839% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5573.039% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.882% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -555.342% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 58.118% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -129.718% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.683% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 82.703% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2236.805% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -9.076% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.888% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 42.323% |
| BioStem Technologies, Inc. | 15.9 Million USD | 90.166% |
| ONE Bio Corp. | 27.49 Million USD | 94.312% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -236.562% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5601.163% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -24.207% |
| Agentix Corp. | 2.51 Million USD | 37.703% |
| LadRx Corporation | 2.2 Million USD | 28.926% |
| Cell Source, Inc. | 15.8 Million USD | 90.105% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3399.195% |
| Regen BioPharma, Inc. | 5.45 Million USD | 71.343% |
| Regen BioPharma, Inc. | 5.45 Million USD | 71.343% |
| NovAccess Global Inc. | 7.86 Million USD | 80.104% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.68% |
| Itoco Inc. | 1.65 Million USD | 5.393% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 23.766% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 74.144% |
| Kadimastem Ltd | 3.5 Million USD | 55.376% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -270.996% |
| CytoDyn Inc. | 127.89 Million USD | 98.777% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3641.716% |
| Mobile Lads Corp. | 1.31 Million USD | -19.071% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 0.152% |
| Qrons Inc. | 1.48 Million USD | -5.057% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 85.84% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -93.374% |
| Rebus Holdings, Inc. | 5.24 Million USD | 70.164% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 74.369% |
| International Stem Cell Corporation | 5.27 Million USD | 70.362% |
| Bioxytran, Inc. | 3.24 Million USD | 51.87% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -149.917% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 66.126% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.185% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 92.976% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 22.78% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 71.449% |
| Neutra Corp. | 973.52 Thousand USD | -60.653% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.61% |
| PureTech Health plc | 125.58 Million USD | 98.755% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 58.372% |
| IXICO plc | 1.9 Million USD | 17.697% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 92.382% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.486% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Cellectis S.A. | 249.36 Million USD | 99.373% |